| The ubiquity of infections makes thier detection a | | | | Key Product Summary: Immunoassay Products, |
| healthcare priority and an ongoing opportunity for | | | | Molecular Diagnostic Products, Amplification |
| IVD companies. The aging of the population, and | | | | Products |
| emerging threats - MRSA, swine flu, and others | | | | Discussion and Listing of 'Home Brew' Products |
| have had an impact on this market recently and | | | | Discussion of Leading Competitors in the Market |
| will continue to in years to come. Kalorama | | | | Increasing Use of Non Traditional Technologies in |
| Information has been observing diagnostic | | | | ID (FISH, Flow Cytometry, etc.) |
| markets for over a decade and has assembled in | | | | The Role of NAT Testing Near-Term and |
| this report, Infectious Disease Diagnostics, | | | | Long-Term |
| Kalorama Information has assembled its best | | | | A Glossary of Important Terms |
| primary and secondary research. | | | | Best Opportunities for IVD Companies |
| This report focuses on products used for the | | | | Market analysis in this report considers primarily |
| diagnosis of bacterial and viral infections. The | | | | the epidemiological considerations and the sizes |
| major consideration is given to bacterial infections | | | | patient groups both in the United States and |
| because (a) they are the most frequent type of | | | | globally, where available. We have accumulated |
| infections, and (b) the practical aspects of | | | | the most recent data available, understanding that |
| diagnosis and therapy are more meaningful based | | | | virtually no organization does extensive studies on |
| both on medial considerations and on market | | | | these applications on a regular basis. |
| considerations. On the other hand, viral infections | | | | As with most Kalorama reports, this is a work of |
| are becoming of greater importance due to (a) | | | | both market description and analysis, along with |
| the discovery of new viral infections, (b) | | | | recommendations. The analysis presented in this |
| advances in the development of viral therapeutics, | | | | report is based on data from a combination of |
| and (c) the mutation viruses that cause drug | | | | company, government, industry, institutional and |
| resistance. | | | | private sources. It includes information from |
| Included in this report: | | | | extensive literature reviews and discussions with |
| Market Size and Forecast for (Immunoassays, | | | | experts in the field, including microbiologists, |
| Rapid, DNA, ID/MIC ) | | | | pathologists, hospital authorities, research |
| Overview of Key Infections and Their Impact on | | | | scientists, business development managers and |
| the Market | | | | marketing managers. |
| Long-Term (10 Year) Trend in the Infectious | | | | In this report global (world) revenue numbers are |
| Disease Diagnostics Market | | | | presented based on reported and estimated |
| Seven Conclusions and Recommendations | | | | manufacturer revenue. |